<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="other"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Data Brief</journal-id><journal-id journal-id-type="iso-abbrev">Data Brief</journal-id><journal-title-group><journal-title>Data in Brief</journal-title></journal-title-group><issn pub-type="epub">2352-3409</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28795098</article-id><article-id pub-id-type="pmc">5537426</article-id><article-id pub-id-type="publisher-id">S2352-3409(17)30335-9</article-id><article-id pub-id-type="doi">10.1016/j.dib.2017.07.033</article-id><article-categories><subj-group subj-group-type="heading"><subject>Medicine and Dentistry</subject></subj-group></article-categories><title-group><article-title>Data on administration of cyclosporine, nicorandil, metoprolol on reperfusion related outcomes in ST-segment Elevation Myocardial Infarction treated with percutaneous coronary intervention</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Campo</surname><given-names>Gianluca</given-names></name><email>cmpglc@unife.it</email><xref rid="aff0005" ref-type="aff">a</xref><xref rid="cor1" ref-type="corresp">&#x0204e;</xref></contrib><contrib contrib-type="author"><name><surname>Pavasini</surname><given-names>Rita</given-names></name><xref rid="aff0005" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name><surname>Morciano</surname><given-names>Giampaolo</given-names></name><xref rid="aff0010" ref-type="aff">b</xref></contrib><contrib contrib-type="author"><name><surname>Lincoff</surname><given-names>Michael A.</given-names></name><xref rid="aff0015" ref-type="aff">c</xref></contrib><contrib contrib-type="author"><name><surname>C. Gibson</surname><given-names>Michael</given-names></name><xref rid="aff0020" ref-type="aff">d</xref></contrib><contrib contrib-type="author"><name><surname>Kitakaze</surname><given-names>Masafumi</given-names></name><xref rid="aff0025" ref-type="aff">e</xref></contrib><contrib contrib-type="author"><name><surname>Lonborg</surname><given-names>Jacob</given-names></name><xref rid="aff0030" ref-type="aff">f</xref></contrib><contrib contrib-type="author"><name><surname>Ahluwalia</surname><given-names>Amrita</given-names></name><xref rid="aff0035" ref-type="aff">g</xref></contrib><contrib contrib-type="author"><name><surname>Ishii</surname><given-names>Hideki</given-names></name><xref rid="aff0040" ref-type="aff">h</xref></contrib><contrib contrib-type="author"><name><surname>Frenneaux</surname><given-names>Michael</given-names></name><xref rid="aff0045" ref-type="aff">i</xref></contrib><contrib contrib-type="author"><name><surname>Ovize</surname><given-names>Michel</given-names></name><xref rid="aff0050" ref-type="aff">j</xref></contrib><contrib contrib-type="author"><name><surname>Galvani</surname><given-names>Marcello</given-names></name><xref rid="aff0055" ref-type="aff">k</xref></contrib><contrib contrib-type="author"><name><surname>Atar</surname><given-names>Dan</given-names></name><xref rid="aff0060" ref-type="aff">l</xref></contrib><contrib contrib-type="author"><name><surname>Ibanez</surname><given-names>Borja</given-names></name><xref rid="aff0065" ref-type="aff">m</xref></contrib><contrib contrib-type="author"><name><surname>Cerisano</surname><given-names>Giampaolo</given-names></name><xref rid="aff0070" ref-type="aff">n</xref></contrib><contrib contrib-type="author"><name><surname>Biscaglia</surname><given-names>Simone</given-names></name><xref rid="aff0005" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name><surname>Neil</surname><given-names>Brandon J.</given-names></name><xref rid="aff0020" ref-type="aff">d</xref></contrib><contrib contrib-type="author"><name><surname>Asakura</surname><given-names>Masanori</given-names></name><xref rid="aff0025" ref-type="aff">e</xref></contrib><contrib contrib-type="author"><name><surname>Engstrom</surname><given-names>Thomas</given-names></name><xref rid="aff0030" ref-type="aff">f</xref></contrib><contrib contrib-type="author"><name><surname>Jones</surname><given-names>Daniel A.</given-names></name><xref rid="aff0035" ref-type="aff">g</xref></contrib><contrib contrib-type="author"><name><surname>Dawson</surname><given-names>Dana</given-names></name><xref rid="aff0075" ref-type="aff">o</xref></contrib><contrib contrib-type="author"><name><surname>Ferrari</surname><given-names>Roberto</given-names></name><xref rid="aff0005" ref-type="aff">a</xref><xref rid="aff0080" ref-type="aff">p</xref></contrib><contrib contrib-type="author"><name><surname>Pinton</surname><given-names>Paolo</given-names></name><xref rid="aff0010" ref-type="aff">b</xref></contrib><contrib contrib-type="author"><name><surname>Ottani</surname><given-names>Filippo</given-names></name><xref rid="aff0055" ref-type="aff">k</xref></contrib></contrib-group><aff id="aff0005"><label>a</label>Cardiology Unit, Azienda Ospedaliero-Universitaria di Ferrara, Cona, FE, Italy</aff><aff id="aff0010"><label>b</label>Department of Morphology, Surgery and Experimental Medicine. Section of Pathology, Oncology and Experimental Biology, University of Ferrara, Ferrara, Italy</aff><aff id="aff0015"><label>c</label>Cleveland Clinic Coordinating Center for Clinical Research (C5Research), Cleveland, OH, USA</aff><aff id="aff0020"><label>d</label>PERFUSE Study Group, Cardiovascular Division, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA</aff><aff id="aff0025"><label>e</label>Cardiovascular Division of Medicine, National Cardiovascular Centre, Suita, Osaka, Japan</aff><aff id="aff0030"><label>f</label>Department of Cardiology, Rigshospitalet, Copenhagen, Denmark</aff><aff id="aff0035"><label>g</label>Centre of Clinical Pharmacology, Barts NIHR Cardiovascular Biomedical Research Unit, William Harvey Research Institute, Barts &#x00026; The London Medical School, Queen Mary University, London, UK</aff><aff id="aff0040"><label>h</label>Department of Cardiology, Nagoya University Graduate School of Medicine, Nagoya, Japan</aff><aff id="aff0045"><label>i</label>Norwich Medical School, University of East Anglia, Norwich, UK</aff><aff id="aff0050"><label>j</label>Clinical Investigation Center of Lyon, Lyon, France</aff><aff id="aff0055"><label>k</label>Unit&#x000e0; Operativa di Cardiologia, Ospedale GB Morgagni, Forl&#x000ec;, Italy</aff><aff id="aff0060"><label>l</label>Department of Cardiology B, Oslo University Hospital Ullevall, and Faculty of Medicine, University of Oslo, Oslo, Norway</aff><aff id="aff0065"><label>m</label>Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain and Instituto de Investigaci&#x000f3;n-Fundaci&#x000f3;n Jim&#x000e9;nez D&#x000ed;az Hospital, Madrid, Spain</aff><aff id="aff0070"><label>n</label>Division of Cardiology, University of Florence, Careggi Hospital, Florence, Italy</aff><aff id="aff0075"><label>o</label>School of Medicine and Dentistry, University of Aberdeen, Aberdeen, UK</aff><aff id="aff0080"><label>p</label>Maria Cecilia Hospital, GVM Care &#x00026; Research, E.S.: Health Science Foundation, Cotignola, Italy</aff><author-notes><corresp id="cor1"><label>&#x0204e;</label>Correspondence to: Cardiovascular Institute, Azienda Ospedaliera Universitaria S. Anna, Via Aldo Moro 8, 44124 Cona, Ferrara, Italy. Fax: +39(0)532241885.Cardiovascular Institute, Azienda Ospedaliera Universitaria S. AnnaVia Aldo Moro 8ConaFerrara44124Italy <email>cmpglc@unife.it</email></corresp></author-notes><pub-date pub-type="pmc-release"><day>18</day><month>7</month><year>2017</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="collection"><month>10</month><year>2017</year></pub-date><pub-date pub-type="epub"><day>18</day><month>7</month><year>2017</year></pub-date><volume>14</volume><fpage>197</fpage><lpage>205</lpage><history><date date-type="received"><day>10</day><month>6</month><year>2017</year></date><date date-type="rev-recd"><day>11</day><month>7</month><year>2017</year></date><date date-type="accepted"><day>13</day><month>7</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; 2017 The Authors</copyright-statement><copyright-year>2017</copyright-year><license license-type="CC BY" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).</license-p></license></permissions><abstract id="ab0010"><p>Mortality and morbidity in patients with ST elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (PCI) are still high <xref rid="bib1" ref-type="bibr">[1]</xref>. A huge amount of the myocardial damage is related to the mitochondrial events happening during reperfusion <xref rid="bib2" ref-type="bibr">[2]</xref>. Several drugs directly and indirectly targeting mitochondria have been administered at the time of the PCI and their effect on fatal (all-cause mortality, cardiovascular (CV) death) and non fatal (hospital readmission for heart failure (HF)) outcomes have been tested showing conflicting results <xref rid="bib3" ref-type="bibr">[3]</xref>, <xref rid="bib4" ref-type="bibr">[4]</xref>, <xref rid="bib5" ref-type="bibr">[5]</xref>, <xref rid="bib6" ref-type="bibr">[6]</xref>, <xref rid="bib7" ref-type="bibr">[7]</xref>, <xref rid="bib8" ref-type="bibr">[8]</xref>, <xref rid="bib9" ref-type="bibr">[9]</xref>, <xref rid="bib10" ref-type="bibr">[10]</xref>, <xref rid="bib11" ref-type="bibr">[11]</xref>, <xref rid="bib12" ref-type="bibr">[12]</xref>, <xref rid="bib13" ref-type="bibr">[13]</xref>, <xref rid="bib14" ref-type="bibr">[14]</xref>, <xref rid="bib15" ref-type="bibr">[15]</xref>, <xref rid="bib16" ref-type="bibr">[16]</xref>. Data from 15 trials have been pooled with the aim to analyze the effect of drug administration versus placebo on outcome <xref rid="bib17" ref-type="bibr">[17]</xref>. Subgroup analysis are here analyzed: considering only randomized clinical trial (RCT) on cyclosporine or nicorandil <xref rid="bib3" ref-type="bibr">[3]</xref>, <xref rid="bib4" ref-type="bibr">[4]</xref>, <xref rid="bib5" ref-type="bibr">[5]</xref>, <xref rid="bib9" ref-type="bibr">[9]</xref>, <xref rid="bib10" ref-type="bibr">[10]</xref>, <xref rid="bib11" ref-type="bibr">[11]</xref>, excluding a trial on metoprolol <xref rid="bib12" ref-type="bibr">[12]</xref> and comparing trial with follow-up length &#x0003c;12 months versus those with longer follow-up <xref rid="bib3" ref-type="bibr">[3]</xref>, <xref rid="bib4" ref-type="bibr">[4]</xref>, <xref rid="bib5" ref-type="bibr">[5]</xref>, <xref rid="bib6" ref-type="bibr">[6]</xref>, <xref rid="bib7" ref-type="bibr">[7]</xref>, <xref rid="bib8" ref-type="bibr">[8]</xref>, <xref rid="bib9" ref-type="bibr">[9]</xref>, <xref rid="bib10" ref-type="bibr">[10]</xref>, <xref rid="bib11" ref-type="bibr">[11]</xref>, <xref rid="bib12" ref-type="bibr">[12]</xref>, <xref rid="bib13" ref-type="bibr">[13]</xref>, <xref rid="bib14" ref-type="bibr">[14]</xref>, <xref rid="bib15" ref-type="bibr">[15]</xref>, <xref rid="bib16" ref-type="bibr">[16]</xref>. This article describes data related article titled &#x0201c;Clinical Benefit of Drugs Targeting Mitochondrial Function as an Adjunct to Reperfusion in ST-segment Elevation Myocardial Infarction: a Meta-Analysis of Randomized Clinical Trials&#x0201d; <xref rid="bib17" ref-type="bibr">[17]</xref>.</p></abstract><kwd-group id="keys0005"><title>Keywords</title><kwd>Reperfusion injury</kwd><kwd>Myocardial infarction</kwd><kwd>PCI</kwd><kwd>Cyclosporin</kwd><kwd>Nicorandil</kwd><kwd>Follow-up</kwd></kwd-group></article-meta></front><body><p><bold>Specifications Table</bold><table-wrap id="t0005" position="float"><alt-text id="at0035">Table</alt-text><table frame="hsides" rules="groups"><tbody><tr><td>Subject area</td><td><italic>Clinical research; meta-analysis</italic></td></tr><tr><td>More specific subject area</td><td><italic>Medicine; Cardiology; Reperfusion injury</italic></td></tr><tr><td>Type of data</td><td><italic>Figure</italic></td></tr><tr><td>How data was acquired</td><td><italic>Meta-analysis</italic></td></tr><tr><td>Data format</td><td><italic>Analyzed</italic></td></tr><tr><td>Experimental factors</td><td><italic>Ciclosporin or nicorandil, exclusion of metoprolol and follow-up length for reperfusion in ST elevation myocardial elevation treated with primary coronary intervention.</italic></td></tr><tr><td>Experimental features</td><td><italic>15 studies focused on drugs targeting mitochondrial function vs. placebo in patients undergoing primary PCI for STEMI, of which 3 with cyclosporine, 2 with nicorandil, only one study with metoprolol were retrieved from MEDLINE, Cochrane Library, Google Scholar and Biomed Central</italic></td></tr><tr><td>Data source location</td><td><italic>Italy, USA, Israel, Japan, Denmark, UK, France, Norway, Spain.</italic></td></tr><tr><td>Data accessibility</td><td><italic>Data is with this article</italic></td></tr></tbody></table></table-wrap></p><p><bold>Value of the data</bold><list list-type="simple"><list-item id="u0005"><label>&#x02022;</label><p>The use of cyclosporine or nicorandil at the time of primary percutaneous coronary angioplasty (PCI) on fatal (all-cause mortality, cardiovascular (CV) death) and non fatal (hospital readmission for heart failure (HF)) outcomes, show the absence of any potential benefit.</p></list-item><list-item id="u0010"><label>&#x02022;</label><p>Excluding a trial on metoprolol <xref rid="bib12" ref-type="bibr">[12]</xref>, which has a complex mechanism of action, not targeting only mitochondrial function, the pooled analysis on fatal and non fatal outcomes of the 14 studies did not changed.</p></list-item><list-item id="u0015"><label>&#x02022;</label><p>The analysis on follow-up length shows effects on hospital readmission for HF for trials with longer follow-up.</p></list-item><list-item id="u0020"><label>&#x02022;</label><p>These additional analyses should be the basis to plan further randomized clinical trials (RCTs) on reperfusion injury in ST elevation myocardial infarction (STEMI) patients undergoing PCI, focusing attention on other molecular mitochondrial targets.</p></list-item><list-item id="u0025"><label>&#x02022;</label><p>New RCTs on reperfusion injury should have a longer follow-up analysis.</p></list-item></list></p><sec id="s0005"><label>1</label><title>Data</title><p>Considering only trial focused on cyclosporine versus placebo, the HR for CV mortality, all-cause mortality and hospital readmission for HF were not statistical significant (<italic>p</italic>=0.33; <italic>p</italic>=0.16; <italic>p</italic>=0.95, respectively) (<xref rid="f0005" ref-type="fig">Fig. 1</xref>). The same data are obtained considering only trials on nicorandil (<italic>p</italic>=0.06 for CV mortality; <italic>p</italic>=0.07 for all-cause death; <italic>p</italic>=0.2 for hospital readmission for HF) (<xref rid="f0010" ref-type="fig">Fig. 2</xref>). After the exclusion of the study on metoprolol from pooled analysis on trials with indirect/unspecific mechanism of action against mitochondrial component/pathway, the HR for CV death, all-cause death and hospital readmission for HF were significantly reduced (<italic>p</italic>=0.03; <italic>p</italic>=0.008; <italic>p</italic>=0.0001, respectively) (<xref rid="f0015" ref-type="fig">Fig. 3</xref>). Finally, the analysis on follow-up on all the studies included in the meta-analysis showed a reduction in hospital readmission for HF in studies with follow-up length &#x02265;12 months (HR 0.46; 95% CI 0.45&#x02013;0.92, <italic>p</italic>=0.03) (<xref rid="f0020" ref-type="fig">Fig. 4</xref>, <xref rid="f0025" ref-type="fig">Fig. 5</xref>, <xref rid="f0030" ref-type="fig">Fig. 6</xref>).<fig id="f0005"><label>Fig. 1</label><caption><p>Forest plots on cardiovascular mortality, all-cause mortality and hospital readmission for HF in studies randomizing to cyclosporine vs. placebo. CV: cardiovascular.</p></caption><alt-text id="at0005">Fig. 1</alt-text><graphic xlink:href="gr1"/></fig><fig id="f0010"><label>Fig. 2</label><caption><p>Forest plots on cardiovascular mortality, all-cause mortality and hospital readmission for HF in studies randomizing to nicorandil vs. placebo. CV: cardiovascular.</p></caption><alt-text id="at0010">Fig. 2</alt-text><graphic xlink:href="gr2"/></fig><fig id="f0015"><label>Fig. 3</label><caption><p>Forest plots on cardiovascular mortality, all-cause mortality and hospital readmission for HF in studies randomizing indirect/unspecific mechanism of action against mitochondrial component/pathway vs. placebo, excluding the study on metoprolol <xref rid="bib12" ref-type="bibr">[12]</xref>. ANP: atrial natriuretic peptide. NIC: nicorandil. CV: cardiovascular. HF: heart failure. hosp: hospitalization.</p></caption><alt-text id="at0015">Fig. 3</alt-text><graphic xlink:href="gr3"/></fig><fig id="f0020"><label>Fig. 4</label><caption><p>Forest plot on cardiovascular mortality after stratification of studies according to follow-up length. SP: safety population. ANT: anterior cohort. INF: inferior cohort. ANP: atrial natriuretic peptide. NIC: nicorandil. CV: cardiovascular.</p></caption><alt-text id="at0020">Fig. 4</alt-text><graphic xlink:href="gr4"/></fig><fig id="f0025"><label>Fig. 5</label><caption><p>Forest plot on all-cause mortality after stratification of studies according follow-up length. SP: safety population. ANT: anterior cohort. INF: inferior cohort. ANP: atrial natriuretic peptide. NIC: nicorandil.</p></caption><alt-text id="at0025">Fig. 5</alt-text><graphic xlink:href="gr5"/></fig><fig id="f0030"><label>Fig. 6</label><caption><p>Forest plot on hospital readmission for heart failure after stratification of studies according follow-up length. SP: safety population. ANT: anterior cohort. INF: inferior cohort. ANP: atrial natriuretic peptide. NIC: nicorandil. HF: heart failure.</p></caption><alt-text id="at0030">Fig. 6</alt-text><graphic xlink:href="gr6"/></fig></p></sec><sec id="s0010"><label>2</label><title>Experimental design, materials and methods</title><sec id="s0015"><label>2.1</label><title>Search strategy</title><p>A systematic review and meta-analysis was performed following Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) criteria <xref rid="bib18" ref-type="bibr">[18]</xref>, <xref rid="bib19" ref-type="bibr">[19]</xref>, <xref rid="bib20" ref-type="bibr">[20]</xref>, <xref rid="bib21" ref-type="bibr">[21]</xref>. The protocol of this study was published on PROSPERO (CRD42016033085).</p><p>Papers were retrieved in MEDLINE, Cochrane Library, Google Scholar and Biomed Central. The terms searched were: (reperfusion injury) AND ((PCI) OR (percutaneous coronary intervention) OR (ST elevation myocardial infarction) OR (STEMI) OR (myocardial infarction)) <xref rid="bib3" ref-type="bibr">[3]</xref>, <xref rid="bib4" ref-type="bibr">[4]</xref>, <xref rid="bib5" ref-type="bibr">[5]</xref>, <xref rid="bib6" ref-type="bibr">[6]</xref>, <xref rid="bib7" ref-type="bibr">[7]</xref>, <xref rid="bib8" ref-type="bibr">[8]</xref>, <xref rid="bib9" ref-type="bibr">[9]</xref>, <xref rid="bib10" ref-type="bibr">[10]</xref>, <xref rid="bib11" ref-type="bibr">[11]</xref>, <xref rid="bib12" ref-type="bibr">[12]</xref>, <xref rid="bib13" ref-type="bibr">[13]</xref>, <xref rid="bib14" ref-type="bibr">[14]</xref>, <xref rid="bib15" ref-type="bibr">[15]</xref>, <xref rid="bib16" ref-type="bibr">[16]</xref>.</p></sec><sec id="s0020"><label>2.2</label><title>Selection criteria</title><p>Detailed description of selection criteria of the papers is described elsewhere <xref rid="bib17" ref-type="bibr">[17]</xref>. In particular, we focused on i) RCTs ii) enrolling STEMI patients; with iii) reperfusion strategy by primary PCI; iv) comparison of agent/drug against RI vs. placebo/gold standard treatment.</p></sec><sec id="s0025"><label>2.3</label><title>Data abstraction, endpoints, contact with authors</title><p>We performed a pre-hoc stratification of studies according to mechanism of action targeting a mitochondrial component/pathway (direct/selective vs. indirect/unspecific) according to a recent overview <xref rid="bib22" ref-type="bibr">[22]</xref>. The analyses were performed according to the following criteria: i) administration of cyclosporine, ii) administration of nicorandil, iii) follow-up length &#x0003c;12 vs. &#x02265;12 months iv) indirect/unspecific drugs after exclusion of the study of Pizarro et al. <xref rid="bib12" ref-type="bibr">[12]</xref>. The primary endpoint of the analysis was the incidence of cardiovascular death. Secondary endpoints were: all-cause death, hospital readmission for heart failure (HF).</p></sec><sec id="s0030"><label>2.4</label><title>Data analysis and synthesis</title><p>The endpoints were expressed as odds ratio (OR). Point estimates and standard errors were calculated and combined by the generic inverse variance method <xref rid="bib23" ref-type="bibr">[23]</xref>, computing risk estimates with 95% confidence intervals according to logarithmic transformation of the OR. A random effect model was used. Statistical heterogeneity was assessed with the Cochran's Q test and the I<sup>2</sup> statistic <xref rid="bib24" ref-type="bibr">[24]</xref>. To test the difference between sub-group analyses the Chi<sup>2</sup> test has been used. Prometa (Internovi, Cesena, Italy) and RevMan 5 (The Cochrane Collaboration, The Nordic Cochrane Centre, Copenhagen, Denmark) software were used for statistical analyses.</p></sec></sec></body><back><ref-list id="bibliog0005"><title>References</title><ref id="bib1"><label>1</label><mixed-citation publication-type="other" id="othref0005">ESC/EACTS guidelines on myocardial revascularization. Eur. Heart J., vol. 35, 2014, pp. 2541&#x02013;2619.</mixed-citation></ref><ref id="bib2"><label>2</label><element-citation publication-type="journal" id="sbref1"><person-group person-group-type="author"><name><surname>Morciano</surname><given-names>G.</given-names></name><name><surname>Giorgi</surname><given-names>C.</given-names></name><name><surname>Bonora</surname><given-names>M.</given-names></name></person-group><article-title>Molecular identity of the mitochondrial permeability transition pore and its role in ischemia-reperfusion injury</article-title><source>J. Mol. Cell. Cardiol.</source><volume>78</volume><year>2015</year><fpage>142</fpage><lpage>153</lpage><pub-id pub-id-type="pmid">25172387</pub-id></element-citation></ref><ref id="bib3"><label>3</label><element-citation publication-type="journal" id="sbref2"><person-group person-group-type="author"><name><surname>Piot</surname><given-names>C.</given-names></name><name><surname>Croisille</surname><given-names>P.</given-names></name><name><surname>Staat</surname><given-names>P.</given-names></name></person-group><article-title>Effect of cyclosporine on reperfusion injury in acute myocardial infarction</article-title><source>N. Engl. J. Med.</source><volume>359</volume><year>2008</year><fpage>473</fpage><lpage>481</lpage><pub-id pub-id-type="pmid">18669426</pub-id></element-citation></ref><ref id="bib4"><label>4</label><element-citation publication-type="journal" id="sbref3"><person-group person-group-type="author"><name><surname>Cung</surname><given-names>T.T.</given-names></name><name><surname>Morel</surname><given-names>O.</given-names></name><name><surname>Cayla</surname><given-names>G.</given-names></name></person-group><article-title>Cyclosporine before PCI in Patients with Acute Myocardial Infarction</article-title><source>N. Engl. J. Med.</source><volume>373</volume><year>2015</year><fpage>1021</fpage><lpage>1031</lpage><pub-id pub-id-type="pmid">26321103</pub-id></element-citation></ref><ref id="bib5"><label>5</label><element-citation publication-type="journal" id="sbref4"><person-group person-group-type="author"><name><surname>Ottani</surname><given-names>F.</given-names></name><name><surname>Latini</surname><given-names>R.</given-names></name><name><surname>Staszewsky</surname><given-names>L.</given-names></name><collab>CYCLE investigators</collab></person-group><article-title>Cyclosporine A in reperfused myocardial infarction: the multicenter, controlled, open-label CYCLE trial</article-title><source>J. Am. Coll. Cardiol.</source><volume>67</volume><year>2016</year><fpage>365</fpage><lpage>374</lpage><pub-id pub-id-type="pmid">26821623</pub-id></element-citation></ref><ref id="bib6"><label>6</label><element-citation publication-type="journal" id="sbref5"><person-group person-group-type="author"><name><surname>Lincoff</surname><given-names>A.M.</given-names></name><name><surname>Roe</surname><given-names>M.</given-names></name><name><surname>Aylward</surname><given-names>P.</given-names></name><collab>PROTECTION AMI investigators</collab></person-group><article-title>Inhibition of delta-protein kinase C by delcasertib as an adjunct to primary percutaneous coronary intervention for acute anterior ST-segment elevation myocardial infarction: results of the PROTECTION AMI randomized controlled trial</article-title><source>Eur. Heart J.</source><volume>35</volume><year>2014</year><fpage>2516</fpage><lpage>2523</lpage><pub-id pub-id-type="pmid">24796339</pub-id></element-citation></ref><ref id="bib7"><label>7</label><element-citation publication-type="journal" id="sbref6"><person-group person-group-type="author"><name><surname>Atar</surname><given-names>D.</given-names></name><name><surname>Arheden</surname><given-names>H.</given-names></name><name><surname>Berdeaux</surname><given-names>A.</given-names></name></person-group><article-title>Effect of intravenous TRO40303 as an adjunct to primary percutaneous coronary intervention for acute ST-elevation myocardial infarction: mitocare study results</article-title><source>Eur. Heart J.</source><volume>36</volume><year>2015</year><fpage>112</fpage><lpage>119</lpage><pub-id pub-id-type="pmid">25179768</pub-id></element-citation></ref><ref id="bib8"><label>8</label><element-citation publication-type="journal" id="sbref7"><person-group person-group-type="author"><name><surname>Gibson</surname><given-names>C.M.</given-names></name><name><surname>Giugliano</surname><given-names>R.P.</given-names></name><name><surname>Kloner</surname><given-names>R.A.</given-names></name></person-group><article-title>EMBRACE STEMI study: a Phase 2a trial to evaluate the safety, tolerability, and efficacy of intravenous MTP-131 on reperfusion injury in patients undergoing primary percutaneous coronary intervention</article-title><source>Eur. Heart J.</source><year>2015</year><comment>(Epub ahead of print)</comment></element-citation></ref><ref id="bib9"><label>9</label><element-citation publication-type="journal" id="sbref8"><person-group person-group-type="author"><name><surname>Ishii</surname><given-names>H.</given-names></name><name><surname>Ichimiya</surname><given-names>S.</given-names></name><name><surname>Kanashiro</surname><given-names>M.</given-names></name></person-group><article-title>Impact of a single intravenous administration of nicorandil before reperfusion in patients with ST-segment-elevation myocardial infarction</article-title><source>Circulation</source><volume>112</volume><year>2005</year><fpage>1284</fpage><lpage>1288</lpage><pub-id pub-id-type="pmid">16116055</pub-id></element-citation></ref><ref id="bib10"><label>10</label><element-citation publication-type="journal" id="sbref9"><person-group person-group-type="author"><name><surname>Kitakaze</surname><given-names>M.</given-names></name><name><surname>Asakura</surname><given-names>M.</given-names></name><name><surname>Kim</surname><given-names>J.</given-names></name><collab>J-WIND investigators</collab></person-group><article-title>Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials</article-title><source>Lancet</source><volume>370</volume><year>2007</year><fpage>1483</fpage><lpage>1493</lpage><pub-id pub-id-type="pmid">17964349</pub-id></element-citation></ref><ref id="bib11"><label>11</label><element-citation publication-type="journal" id="sbref10"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>H.C.</given-names></name><name><surname>An</surname><given-names>S.G.</given-names></name><name><surname>Choi</surname><given-names>J.H.</given-names></name></person-group><article-title>Effect of intra-coronary nicorandil administration prior to reperfusion in acute ST segment elevation myocardial infarction</article-title><source>Circ. J.</source><volume>72</volume><year>2008</year><fpage>1425</fpage><lpage>1429</lpage><pub-id pub-id-type="pmid">18724016</pub-id></element-citation></ref><ref id="bib12"><label>12</label><element-citation publication-type="journal" id="sbref11"><person-group person-group-type="author"><name><surname>Pizarro</surname><given-names>G.</given-names></name><name><surname>Fern&#x000e1;ndez-Friera</surname><given-names>L.</given-names></name><name><surname>Fuster</surname><given-names>V.</given-names></name></person-group><article-title>Long-term benefit of early pre-reperfusion metoprolol administration in patients with acute myocardial infarction: results from the METOCARD-CNIC trial (Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction)</article-title><source>J Am. Coll. Cardiol.</source><volume>63</volume><year>2014</year><fpage>2356</fpage><lpage>2362</lpage><pub-id pub-id-type="pmid">24694530</pub-id></element-citation></ref><ref id="bib13"><label>13</label><element-citation publication-type="journal" id="sbref12"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>D.A.</given-names></name><name><surname>Pellaton</surname><given-names>C.</given-names></name><name><surname>Velmurugan</surname><given-names>S.</given-names></name></person-group><article-title>Randomized phase 2 trial of intracoronary nitrite during acute myocardial infarction</article-title><source>Circ. Res.</source><volume>116</volume><year>2015</year><fpage>437</fpage><lpage>447</lpage><pub-id pub-id-type="pmid">25512434</pub-id></element-citation></ref><ref id="bib14"><label>14</label><element-citation publication-type="journal" id="sbref13"><person-group person-group-type="author"><name><surname>L&#x000f8;nborg</surname><given-names>J.</given-names></name><name><surname>Vejlstrup</surname><given-names>N.</given-names></name><name><surname>Kelb&#x000e6;k</surname><given-names>H.</given-names></name></person-group><article-title>Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction</article-title><source>Eur. Heart J</source><volume>33</volume><year>2012</year><fpage>1491</fpage><lpage>1499</lpage><pub-id pub-id-type="pmid">21920963</pub-id></element-citation></ref><ref id="bib15"><label>15</label><element-citation publication-type="journal" id="sbref14"><person-group person-group-type="author"><name><surname>Siddiqi</surname><given-names>N.</given-names></name><name><surname>Neil</surname><given-names>C.</given-names></name><name><surname>Bruce</surname><given-names>M.</given-names></name><collab>NIAMI investigators</collab></person-group><article-title>Intravenous sodium nitrite in acute ST-elevation myocardial infarction: a randomized controlled trial (NIAMI)</article-title><source>Eur. Heart J.</source><volume>35</volume><year>2014</year><fpage>1255</fpage><lpage>1262</lpage><pub-id pub-id-type="pmid">24639423</pub-id></element-citation></ref><ref id="bib16"><label>16</label><element-citation publication-type="journal" id="sbref15"><person-group person-group-type="author"><name><surname>Cerisano</surname><given-names>G.</given-names></name><name><surname>Buonamici</surname><given-names>P.</given-names></name><name><surname>Valenti</surname><given-names>R.</given-names></name></person-group><article-title>Early short-term doxycycline therapy in patients with acute myocardial infarction and left ventricular dysfunction to prevent the ominous progression to adverse remodelling: the TIPTOP trial</article-title><source>Eur. Heart J.</source><volume>35</volume><year>2014</year><fpage>184</fpage><lpage>191</lpage><pub-id pub-id-type="pmid">24104875</pub-id></element-citation></ref><ref id="bib17"><label>17</label><element-citation publication-type="journal" id="sbref16"><person-group person-group-type="author"><name><surname>Campo</surname><given-names>G.</given-names></name><name><surname>Pavasini</surname><given-names>R.</given-names></name><name><surname>Morciano</surname><given-names>G.</given-names></name></person-group><article-title>Clinical benefit of drugs targeting mitochondrial function as an adjunct to reperfusion in ST-segment elevation myocardial infarction: a meta-analysis of randomized clinical trials</article-title><source>Int. J. Cardiol.</source><year>2017</year><comment>(epub ahead of print)</comment></element-citation></ref><ref id="bib18"><label>18</label><element-citation publication-type="journal" id="sbref17"><person-group person-group-type="author"><name><surname>Moher</surname><given-names>D.</given-names></name><name><surname>Cook</surname><given-names>D.J.</given-names></name><name><surname>Eastwood</surname><given-names>S.</given-names></name><name><surname>Olkin</surname><given-names>I.</given-names></name><name><surname>Rennie</surname><given-names>D.</given-names></name><name><surname>Stroup</surname><given-names>D.F.</given-names></name></person-group><article-title>Improving the quality of reports of meta-analyses of randomized controlled trials: the QUOROM statement</article-title><source>Lancet</source><volume>354</volume><year>1999</year><fpage>1896</fpage><lpage>1900</lpage><pub-id pub-id-type="pmid">10584742</pub-id></element-citation></ref><ref id="bib19"><label>19</label><element-citation publication-type="journal" id="sbref18"><person-group person-group-type="author"><name><surname>Stroup</surname><given-names>D.F.</given-names></name><name><surname>Berlin</surname><given-names>J.A.</given-names></name><name><surname>Morton</surname><given-names>S.C.</given-names></name></person-group><article-title>Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-Analysis of Observational Studies in Epidemiology (MOOSE) group</article-title><source>JAMA</source><volume>283</volume><year>2000</year><fpage>2008</fpage><lpage>2012</lpage><pub-id pub-id-type="pmid">10789670</pub-id></element-citation></ref><ref id="bib20"><label>20</label><mixed-citation publication-type="other" id="othref0010">J. Higgins, S. Green, Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0, The Cochrane Collaboration, 2009. <ext-link ext-link-type="uri" xlink:href="http://handbook.cochrane.org" id="ir0010">&#x02329;http://handbook.cochrane.org&#x0232a;</ext-link>. (2011, Accessed 28 December, 2015).</mixed-citation></ref><ref id="bib21"><label>21</label><element-citation publication-type="journal" id="sbref19"><person-group person-group-type="author"><name><surname>Liberati</surname><given-names>A.</given-names></name><name><surname>Altman</surname><given-names>D.G.</given-names></name><name><surname>Tetzlaff</surname><given-names>J.</given-names></name></person-group><article-title>The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration</article-title><source>BMJ</source><volume>339</volume><year>2009</year><fpage>b2700</fpage><pub-id pub-id-type="pmid">19622552</pub-id></element-citation></ref><ref id="bib22"><label>22</label><element-citation publication-type="journal" id="sbref20"><person-group person-group-type="author"><name><surname>Bulluck</surname><given-names>H.</given-names></name><name><surname>Yellon</surname><given-names>D.M.</given-names></name><name><surname>Hausenloy</surname><given-names>D.J.</given-names></name></person-group><article-title>Reducing myocardial infarct size: challenges and future opportunities</article-title><source>Heart</source><volume>102</volume><year>2016</year><fpage>341</fpage><lpage>348</lpage><pub-id pub-id-type="pmid">26674987</pub-id></element-citation></ref><ref id="bib23"><label>23</label><element-citation publication-type="journal" id="sbref21"><person-group person-group-type="author"><name><surname>DerSimonian</surname><given-names>R.</given-names></name><name><surname>Laird</surname><given-names>N.</given-names></name></person-group><article-title>Meta-analysis in clinical trials</article-title><source>Control Clin. Trial</source><volume>7</volume><year>1986</year><fpage>177</fpage><lpage>188</lpage></element-citation></ref><ref id="bib24"><label>24</label><element-citation publication-type="journal" id="sbref22"><person-group person-group-type="author"><name><surname>Higgins</surname><given-names>J.P.</given-names></name><name><surname>Thompson</surname><given-names>S.G.</given-names></name><name><surname>Deeks</surname><given-names>J.J.</given-names></name><name><surname>Altman</surname><given-names>D.G.</given-names></name></person-group><article-title>Measuring inconsistency in meta-analyses</article-title><source>BMJ</source><volume>327</volume><year>2003</year><fpage>557</fpage><lpage>560</lpage><pub-id pub-id-type="pmid">12958120</pub-id></element-citation></ref></ref-list><sec id="s0040" sec-type="supplementary-material"><label>Transparency document</label><title>Supplementary material</title><p><supplementary-material content-type="local-data" id="ec0005"><caption><p>Supplementary material</p></caption><media xlink:href="mmc1.pdf"/></supplementary-material>.</p></sec><ack id="ack0005"><title>Acknowledgements</title><p>Conflict of interest: Lincoff receives research support from Kai Pharmaceuticals; Gibson receives research support from Stealth pharmaceuticals; other authors do not declare conflict of interest.</p><p>Funding: none.</p></ack><fn-group><fn id="s0035" fn-type="supplementary-material"><label>Transparency document</label><p>Transparency data associated with this article can be found in the online version at <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.dib.2017.07.033" id="ir0005">doi:10.1016/j.dib.2017.07.033</ext-link>.</p></fn></fn-group></back></article>